Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - amisulpride - tablets - 50 milligram - amisulpride

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - amisulpride - tablets - 200 milligram - amisulpride

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - amisulpride - film coated tablet - 400 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - amisulpride - tablet - 50 milligram(s) - benzamides; amisulpride

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - amisulpride - tablet - 200 milligram(s) - benzamides; amisulpride

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; methylcellulose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; methylcellulose; lactose monohydrate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; methylcellulose; magnesium stearate; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: macrogol 6000; methylcellulose; purified talc; magnesium stearate; sodium starch glycollate type a; microcrystalline cellulose; basic butylated methacrylate copolymer; titanium dioxide; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amisulpride 400mg;   - film coated tablet - 400 mg - active: amisulpride 400mg   excipient: basic butylated methacrylate copolymer isopropyl alcohol lactose monohydrate macrogol 6000 magnesium stearate   methylcellulose microcrystalline cellulose purified talc purified water sodium starch glycolate titanium dioxide - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.